Abstract
Genetic variability affects the response to numerous xenobiotics but its role in the clinically-observed irregular responses to general anesthetics remains uncertain. To investigate the pharmacogenetics of volatile general anesthetics (VGAs), we developed a Serial Anesthesia Array apparatus to expose multiple Drosophila melanogaster samples to VGAs and behavioral assays to determine pharmacokinetic and pharmacodynamic properties of VGAs. We studied the VGAs isoflurane and sevoflurane in four wild type strains from the Drosophila Genetic Reference Panel, two commonly used laboratory strains (Canton S and w1118), and a mutant in Complex I of the mitochondrial electron transport chain (ND2360114). In all seven strains, isoflurane was more potent than sevoflurane, as predicted by their relative lipid solubilities, and emergence from isoflurane was slower than from sevoflurane, reproducing cardinal pharmacokinetic and pharmacodynamic properties in mammals. In addition, ND2360114 flies were more sensitive to both agents, as observed in worms, mice, and humans carrying Complex I mutations. Moreover, we found substantial variability among the fly strains both in absolute and in relative pharmacokinetic and pharmacodynamic profiles of isoflurane and sevoflurane. These data indicate that naturally occurring genetic variations measurably influence cardinal pharmacologic properties of VGAs and that flies can be used to identify relevant genetic variations.
Similar content being viewed by others
Introduction
Isoflurane (ISO) and sevoflurane (SEVO) are chemically closely related volatile general anesthetics (VGAs) with distinct properties1,2. Like all other VGAs, ISO and SEVO achieve the anesthetic phenotype within a very narrow concentration range3. However, deviations in susceptibility to anesthetics exist: inbred strains of rodents differ in sensitivity to ISO4,5,6 and enflurane7. Individual mongrel cats show differential sensitivity to modern VGAs8 as do segregated human populations for SEVO9,10,11. These data raise the possibility that anesthetic sensitivity may behave like a quantitative trait12,13, as opposed to being mediated by a small number of discrete molecular targets. By contrast, Mendelian mutations have pronounced effects on the sensitivity to VGAs in model organisms14,15,16 and can result in life-threatening consequences17,18. Therefore, as for other xenobiotics19,20, genetic polymorphisms that place a phenotypically normal individual at increased risk for adverse effects from exposure to VGAs are likely to exist.
To facilitate research into anesthetic pharmacogenomics, we took advantage of the genetically accessible fruit fly Drosophila melanogaster. Flies are not humans, yet evolution has produced cellular and molecular mechanisms that are conserved between flies and humans. For example, 55% to 75% of disease-causing genes in humans have functional homologues in flies21. Furthermore, because of evolutionary conservation, findings initially made in flies have made possible clinically important discoveries in higher organisms. Therefore, we used flies to establish the extent to which key pharmacokinetic (PK: ‘how an organism affects a drug’) and pharmacodynamic (PD: ‘how a drug affects an organism’) properties of ISO and SEVO are conserved in flies. This included testing whether a hypomorphic mutation in Complex I of the mitochondrial electron transport chain (ETC) reproduces the hypersensitive phenotype observed in Caenorhabditis elegans, Mus musculus, and Homo sapiens22,23,24,25 as well as examining the variability of PK and PD properties in a natural fly population, the Drosophila Genetic Reference Panel (DGRP).
Our data reveal substantial variability of PK and PD profiles for ISO and SEVO among genetically diverse wild type flies and support the usefulness of flies for pharmacogenomic and toxicological research.
Results
Design of the Serial Anesthesia Array
To allow comparative studies of VGA pharmacology on a medium-throughput scale in Drosophila with different genetic backgrounds, we assembled the Serial Anesthesia Array from easily accessible components. In the configuration shown in Fig. 1A,B, the array has eight tube positions for experimental samples and one tube position for humidification of the carrier gas (8 + 1 configuration). The tubes are arranged in series with a total volume of 655 mL downstream of a vaporizer and an air cylinder. Each tube can hold thousands of flies, but we standardly used fewer than 100 flies per tube. The array provides a simple system with a small footprint capable of delivering any volatile agent with precise and flexible control of the dose (concentration X duration of exposure) simultaneously to multiple experimental samples, e.g. flies of different age, sex, or genotype. Furthermore, neither the concentration nor the duration of VGA administration is constrained by a behavioral endpoint (e.g. loss of postural control) that limits the dose of VGA that can be delivered in traditional inebriometer or separator devices26,27,28.
Gas exchange in the array is rapid
We tested the dynamics of anesthetic delivery through the array by measuring the rise in anesthetic concentration in the most downstream position (tube 8) (Fig. 1A,B). Analysis by gas chromatography showed that the ISO concentration rose with a time constant τ of 0.83 min (Fig. 1C). For a single compartment of the same volume (655 mL), the calculated τ would be 0.44 min. The slower than expected rise in ISO concentration is probably due to turbulence and inhomogeneity of gas exchange during the transition through nine separate tubes as opposed to uptake into flies whose biomass is negligible in comparison to the volume of the tubes. However, gas exchange was efficient enough to reach 95% of the set ISO concentration in the most downstream position within 2.5 min. We conclude that gas exchange in the array permits efficient and rapid administration of VGAs.
Behavioral assays as measures of anesthetic PK and PD
We developed behavioral assays to characterize the PK and PD of VGAs. Like the Dispersion assay developed by Nash and colleagues29, our Early Recovery Time and Percent Active assays are based on the innate, startle-induced climbing behavior of Drosophila. Contrary to the passive assays employed in inebriometer or separator chambers, which use loss of resistance to gravity as a measure of anesthetic depth30,31,32, our assays rely on the integrated function of different behaviors, including the escape reflex in response to mechanical stress, negative geotaxis proper (an innate orienting response and movement in opposition to gravitational cues), climbing ability, and locomotor activity itself, thereby capturing a more complex behavior.
Early Recovery Time is a measure of the time to recovery from a standard VGA dose (2% ISO or 3.5% SEVO for 1 hr) that produces deep anesthesia. After venting the anesthetic from the vial, startle-induced climbing behavior was elicited by manually tapping the vial on a rubber pad to knock the flies to the bottom of the vial once per minute until 6 of 60 flies (10%) were able to climb above 2 cm in 10 sec. Unanesthetized flies easily met this criterion upon the first tap. Thus, Early Recovery Time captures the PK of initial emergence from anesthesia.
The Percent Active is the percentage of 10 flies that climb above 2 cm in 1 min after climbing is elicited by manually tapping the vial. We used the Percent Active assay to determine the half-maximal time to recovery (TtR50). This was done by exposing flies to standard VGA concentrations (2% ISO or 3.5% SEVO) for 1 hr followed by venting the anesthetic from the vial and repeating the Percent Active measurement in the absence of anesthetic until all flies met the climbing criterion (above 2 cm in 1 min). The TtR50 is the amount of time needed for 50% of the flies in a vial to climb above 2 cm in 1 min, and it is an indication of the PK of extensive recovery from anesthesia.
We also used the Percent Active assay to determine the half-maximal effective concentration (EC50) of a VGA. This was done by exposing flies to different anesthetic concentrations for 10 min, measuring the Percent Active in the presence of anesthetic, increasing the anesthetic concentration, and repeating the Percent Active measurement until no flies met the climbing criterion (above 2 cm in 1 min). We chose a 10 min exposure to ensure complete equilibration of the fly brain with the VGA, which is estimated to take approximately 1 min33,34. The EC50 is an indication of the PD of induction of anesthesia.
The Serial Anesthesia Array delivers equivalent concentrations of anesthetic to all positions
We designed the Serial Anesthesia Array to compare anesthetic PK and PD on a medium-throughput experimental scale among different VGAs and different experimental samples. For the latter goal, it is important that all positions arranged in series in the array yield comparable experimental conditions. Therefore, we performed a functional characterization of the array by comparing Percent Active and Early Recovery Time measurements of w1118 flies (a standard laboratory strain) in different positions of the array. We found that the Percent Active did not differ between male flies exposed to 0.4% ISO for 10 min in the most upstream position (tube 1) and the most downstream position (tube 8) (42.09 ± 4.02 and 43.83 ± 4.31, respectively, Fig. 2A). Similarly, Early Recovery Time of mixed sex w1118 flies ranged from 19.0 ± 1.0 min to 25.0 ± 1.0 min but did not differ systematically among positions in the array (P = 0.36, one-way ANOVA) (Fig. 2B). In summary, these results indicate that the Serial Anesthesia Array rapidly delivers equivalent doses of anesthetic to flies in all positions, thereby making it possible to study the effects of anesthetics on multiple fly samples at the same time.
Sex but not age affects the PK properties of VGAs
To test whether age at the time of exposure influences recovery from deep anesthesia, we measured Early Recovery Time in mixed sex w1118 flies grouped in 3-day age increments from 0–2 to 26–28 days old. At all ages, recovery was faster from SEVO than ISO, but age did not affect the speed of recovery from either anesthetic (ISO P = 0.98 and SEVO P = 0.89, one-way ANOVA) (Fig. 3A). Hence, as in humans, the PK of these agents is stable in adulthood35. However, sex did affect the recovery from both anesthetics. We found that 1–7 day old w1118 and Canton S (two standard wild type strains) males recovered about twice as fast as females (Fig. 3B and Supplemental Fig. 1).
Deep anesthesia does not affect lifespan
We tested whether administration of anesthesia to mixed sex w1118 flies at 0–7 days old affected lifespan. After exposures ranging from 0.5 to 5 hr to either 2% ISO or 3.5% SEVO the percentage of surviving flies was determined until all flies had died (Fig. 4A,B and Supplemental Figs 2–4). Neither the duration of exposure nor the anesthetic agent affected the median or maximum lifespan (Fig. 4C,D). Furthermore, exposure of 1–8 day old male or female w1118 flies to 2% ISO or 3.5% SEVO for 2 hr had no effect on the median or maximum lifespan (Fig. 4E,F and Supplemental Fig. 4). We conclude that, as in rodents36, a single exposure to VGAs does not influence lifespan in healthy flies.
PK and PD properties of VGA in flies are similar to mammals
Studies comparing the potency of VGAs using the immobility-based minimum alveolar concentration of anesthetic (MAC) concept, which is assumed to reflect the concentration in the central nervous system, yield remarkably consistent results across all mammalian species and all VGAs3. MAC relies on a binary score (purposeful limb movement: yes or no) scaled to deep levels of anesthesia that is insensitive to quantitative nuances. More important, in mammals, MAC readout is determined by drug action in the spinal cord as opposed to the brain37,38. Therefore, applying the classic definition of MAC to invertebrates is problematic due to the difficulty of translating this classic endpoint to organisms with alternative behavioral repertoires39. Hence, researchers have developed a variety of species-specific behavioral endpoints to position experiments in invertebrates into pharmacologically meaningful contexts with studies in mammals. These endpoint definitions have resulted in a wide range of reported EC50s even for a single agent and a single fly strain, e.g. the EC50s for ISO in Canton S was 0.36 ± 0.04 v/v % in our hands and ranged from 0.20% to 0.71% in the literature40,41.
To determine the extent to which clinically important PK and PD properties of VGAs are reproducible in flies, we used the Percent Active assay to compare anesthetic dynamics of ISO and SEVO in w1118 flies. Because sex affects PK properties (Fig. 3B), only males were used for these studies. In 1–7 day old w1118 males, ISO was more potent than SEVO (EC50: 0.41 ± 0.03 v/v % and 0.68 ± 0.05 v/v %, respectively) with a potency ratio (ISO/SEVO) of 0.60 (0.41/0.68) (Fig. 5A and Table 1). Recovery from deep anesthesia was significantly faster for SEVO than for ISO (TtR50: 11.66 ± 0.77 min and 22.94 ± 1.0 min, respectively) with a recovery ratio (ISO/SEVO) of 1.97 (22.94/11.66) (Fig. 5F and Table 1). The potency and recovery differences between ISO and SEVO in flies are consistent with differences observed in humans42.
A mitochondrial mutation increases the potency of VGAs
One of the potential uses of the Serial Anesthesia Array is to identify heritable genetic variations that affect responses to anesthesia. To explore this possibility, we characterized the behavioral responses of ND23 mutant flies to ISO and SEVO. ND23 is a nuclear gene that encodes a core subunit of Complex I of the mitochondrial electron transport chain. Mutations in subunits of eukaryotic Complex 1, which contains at least 45 distinct subunits, lead to increased sensitivity to VGAs in C. elegans22,23,43, mice24 and humans25; however, the effects of mutations in ND23 (known as T20H4.5 in C. elegans and NDUFS8 in humans) on anesthetic sensitivity have not been studied in any organism. To assess whether the ND2360114 mutation sensitizes flies to anesthetics, we determined the EC50 for ISO and SEVO in 2–4 day old male flies. For both VGAs, the EC50 of ND2360114 flies was lower than that of its control background strain Canton S as well as w1118 (Fig. 6 and Table 1). We conclude that ND23 confers resistance to VGAs.
Genomic variation influences the PD and PK properties of VGAs
To explore the pharmacogenomics of VGAs in natural populations we determined the potency and the recovery profiles for ISO and SEVO in two standard laboratory strains (w1118 and Canton S) and four strains derived from a natural population (RAL161, 352, 774, 892). The specific RAL lines were chosen from opposite ends of the mortality spectrum from blunt trauma determined in 179 RAL lines44 from the Drosophila Genetic Reference Panel (DGRP)45: RAL352 and 774 are at the low end, while RAL161 and 892 are at the high end of the mortality spectrum44. In all RAL lines, ISO was more potent than SEVO (Fig. 5, Table 1). However, their potency ratios (ISO EC50/SEVO EC50) varied from 0.32 ± 0.04 (RAL774) to 0.53 ± 0.14 (RAL352) (Table 1). No correlation between the previously determined blunt trauma resilience and sensitivity to VGAs was discernible. ND2360114 was more sensitive to VGAs than all other lines tested: the ISO EC50 of the most sensitive tested RAL line (RAL352) was 35% higher than that of ND2360114 and the EC50 of SEVO was 9% higher. The potency ratios (ISO/SEVO) of all seven lines ranged from 0.32 ± 0.04 (RAL774) to 0.60 ± 0.05 (w1118) (Fig. 7A and Table 1). These results indicate that natural and laboratory populations harbor genetic polymorphisms that differentially modify the behavioral response to chemically closely-related VGAs.
We also examined the extent to which genetic variation influences recovery from VGAs, a PK parameter not previously examined in invertebrate model organisms. In RAL lines, the ISO TtR50s ranged from 15.37 ± 0.79 min (RAL892) to 37.86 ± 1.26 min (RAL161) and the TtR50s for SEVO ranged from 10.46 ± 0.46 min (RAL892) to 25.71 ± 1.96 min (RAL161) (Figs 5F–J and 7B, and Table 1). As in w1118 flies, recovery from SEVO was faster than from ISO in all tested RAL lines, but the absolute speed of recovery and relative speed of recovery (i.e., ISO TtR50/SEVO TtR50) were different among the four lines (Table 1). These results indicate that both PD and PK profiles (reflected in the EC50 and TtR50, respectively) of VGAs are influenced by genetic background.
Discussion
We have modified existing experimental systems for studying VGAs in flies with the goal of efficiently comparing the effect profiles of VGAs, including PD and PK measures, across different genotypes and experimental interventions. The Serial Anesthesia Array administers identical anesthetic concentrations to multiple samples (Fig. 1A,B) with fast equilibration in all positions (Fig. 1C), assuring equal anesthetic exposure of all samples (Fig. 2). Each position in the array accommodates large numbers of flies providing robust measures for the condition under study. Furthermore, the array offers the ability to simultaneously examine different variables such as age and genotype under the exact same anesthetic dose (Figs 4–7). Using this system, we obtained robust and reproducible results that demonstrate that genetic background significantly modulates the responses to VGAs in flies.
The relative potencies of VGAs are key factors determining their use in clinical practice. We developed the Percent Active assay because reproducing MAC (the standard assay for potency in mammals46) in invertebrate model organisms is laborious, indirect and operator-dependent47,48,49,50,51. Using the Percent Active assay, we compared VGA potency across multiple fly lines (Figs 5–7 and Table 1). The resulting EC50s for ISO are comparable to those determined using analogous assays33,34,40, confirming the robustness of the fly model across laboratories. Furthermore, variability in the ISO/SEVO potency and recovery ratios among fly lines demonstrates that natural populations harbor a diversity of genetic polymorphisms that differentially modulate the potency of and the recovery from two prototypical VGAs (Table 1). In this context, it is notable that the potency ratio of the mitochondrial Complex I mutant ND2360114 was very close to that of its background strain Canton S despite substantially higher sensitivity (Fig. 6. and Table 1). This finding indicates that reduced activity of the electron transport chain proportionally affects the sensitivity to ISO and SEVO.
In addition to potency, the rate of recovery from anesthesia is a critical characteristic of all general anesthetics. We are not aware of any studies addressing recovery from VGAs in invertebrates. Therefore, we developed two behavioral assays, Early Recovery Time and Percent Active, to determine the PK of recovery from anesthesia in flies. Both assays demonstrated substantially faster recovery from SEVO compared with ISO replicating the situation in humans (Figs 3, 5, and 7; Supplemental Fig. 6; and Table 1)42. To compare recovery times among strains we use the ISO/SEVO recovery ratio derived from time-to-recovery measurements (Table 1). Its value varied considerably from 1.28 ± 0.13 (Canton S) to 1.97 ± 0.16 (w1118) bracketing the recovery ratio of 1.63 determined in Sprague-Dawley rats52. The range of absolute and relative potencies and recovery rates determined in RAL lines illustrate the degree to which variability in naturally occurring genetic architecture influences anesthetic PK and PD.
Recovery from VGAs is determined by the rate of elimination of the agent from the body, which occurs via the lungs in mammals and by diffusion out of tracheae, which is independent of circulation, in flies. As both ISO and SEVO undergo minimal metabolism in mammals, enzyme polymorphisms (the primary cause of differences in PK for the majority of xenobiotics)19 are unlikely to account for differences in the TtR50 that we observed. To reconcile our comparative findings for ISO and SEVO with standard understanding of VGA PK and PD, we consider the following possibilities. If diffusion out of the body alone determined the speed of recovery, ISO/SEVO TtR50 ratios should be similar among strains (which are all of similar size). However, we found that TtR50 ratios varied considerably (Table 1). Alternatively, if recovery was simply following declining drug concentrations at the target site, the degree of recovery from an agent should lag in a ‘sensitive’ strain (i.e. lower EC50) behind that in a ‘resistant’ strain (i.e. high EC50) because at equal brain concentration of agent a higher fraction of sensitive animals would be anesthetized. If this was the case, the EC50 would inversely correlate with TtR50. However, we found no correlation between the EC50 and the TtR50 (Fig. 7D). Lastly, a difference in brain dynamics may account for the lack of correlation between the EC50 and TtR50. The EC50 captures the transition from awake to anesthetized state, while the TtR50 quantifies the transition from anesthetized to awake state. Experiments with VGAs in flies and in mice demonstrate that the directionality of change in brain states, that is loss vs. recovery of function, occur at different points of a dose-response relationship33. Furthermore, the points differ among VGAs33 and, as suggested by our experiments, may differ among ‘wildtype’ strains. Together, these data indicate that genetic background influences the responsiveness to anesthetics in multiple ways.
Hypomorphic mutations in Complex I of the mitochondrial electron transport chain result in hypersensitivity to VGAs in humans25, mice53, and worms23. To the best of our knowledge, ND2360114 is the first description of a mutation in the electron transport chain affecting a phenotype under anesthesia in flies. ND23 is an ortholog of NDUFS8 in mammals and T20H4.5 in C. elegans. In humans, mutations in NDUFS8 are associated with Leigh syndrome, a progressive neurological degenerative disorder with onset in infancy or childhood54. RNAi knockdown of T20H4.5 renders worms sensitive to halothane-induced immobilization, reducing the EC50 from 3.2% to 2.1%55. For the majority of mutations tested for VGA responsiveness in flies and worms, an understanding of the gene products and regulatory pathways affected is largely incomplete. However, mutations in core subunits of Complex I of the electron transport chain consistently result in varying degrees of hypersensitivity to most VGAs in worms22,43,55 and our data suggest that the same is true in flies. This finding indicates that a common molecular nexus located in mitochondria influences the potency of halothane, ISO, and SEVO and possibly other potent modern inhalational agents. However, mutants with increased anesthetic sensitivity unrelated to mitochondrial proteins have also been described31,56. So, while a research focus on mitochondrial genes is warranted, it is unlikely to completely explain open questions such as why there is a lack of correlation between the EC50 and TtR50.
In summary, genetic variability in the response to VGAs is relevant because phenotypically silent polymorphisms may directly modify not only the dose of anesthetics needed for surgery but also the likelihood of an individual experiencing the deleterious long-term collateral effects of VGAs (acute cognitive disorders, accelerated neurodegeneration, alterations in immune and inflammatory functions). The latter aspect may be more important as it may affect clinically relevant outcomes in surgical populations. So far, genomic modifiers of VGA sensitivity have been largely neglected in clinical studies examining potential long-term sequelae of exposure to VGAs. We expect that newly developed methods for the identification of quantitative trait loci in flies45,57,58, which have already been successfully applied to xenobiotic toxicology59, will contribute to bridging anesthetic phenotype to genotype.
Materials and Methods
Fly lines and culturing
All flies were maintained on standard molasses food containing 30 g Difco granulated agar (Becton-Dickinson, Sparks, MD), 44 g YSC-1 yeast (Sigma, St. Louis, MO), 328 g cornmeal (Lab Scientific, Highlands, NJ), 400 ml unsulphured Grandma’s molasses (Lab Scientific), 3.6 L water, 40 ml propionic acid (Sigma), and tegosept (8 g Methyl 4-hydroxybenzoate in 75 ml 95% ethanol) (Sigma). DGRP strains were obtained from the Bloomington Stock Center. The ND2360114 line is an EMS mutant line from the Ganetzky lab temperature-sensitive paralytic collection. Mix sex fly samples contained males and females in a 1:1 ratio (Supplemental Fig. 5). w1118 and DGRP flies were maintained at 25 °C. In Fig. 6, Canton S and ND2360114 flies were maintained at 25 °C and then switched to 29 °C at 0–2 days post-eclosion for the remainder of the experiment. In Supplemental Figs 1 and 6, Canton S flies were maintained at 25 °C.
Serial Anesthesia Array assembly, operation, and characterization
The Serial Anesthesia Array was constructed using Falcon 50 mL conical tubes (Fisher Scientific, Waltham, MA), polystyrene serological pipettes (Fisher Scientific), Tygon tubing AAC00022 5/16″ ID × 7/16″ OD (Saint-Gobain North America, Malvern, PA), a Bel-Art paddle style flow indicator model 19937-0003 (Cole-Parmer, Vernon Hills, IL), and calibrated, agent-specific Tec 7 vaporizers (Datex-Ohmeda, Inc., Madison, WI). ISO and SEVO were obtained from Piramal Enterprises Ltd. (Maharashtra, India). Additional details about assembly and operation of the array are provided in Fig. 1A,B and the Results section. A GOW-MAC Series 580 flame ionization gas chromatograph (GOW-MAC Instrument Co., Bethlehem, PA) calibrated with 1% ISO (Calibration cylinder, Air Liquide Healthcare, Madison, WI) was used to measure ISO concentrations. The time constant (τ) for ISO was calculated using the equation CArray = CAF (1-e−T/τ), where CArray is the anesthetic concentration in the array, CAF is the anesthetic concentration flowing into the array, T is sampling time after initiation of air flow, and τ is the time constant [τ = (capacity of the array in mL)/(flow rate mL/min)]. Using this equation and gas chromatograph measurements yielded the experimental time constant of the array (Fig. 1C).
Behavioral and lifespan assays
Effects of anesthetics on flies were quantified using customized, negative geotaxis-based behavioral Early Recovery Time and Percent Active assays, described in the Results section. To determine median and maximum lifespans after exposure to 2% ISO or 3.5% SEVO for various times, flies were cultured on molasses food at 25 °C and transferred to fresh food every 3–4 days. The number of dead flies was recorded daily (except weekends) until all flies had died. Additional details are provided in Fig. 4 and Supplemental Figs 2–4.
Data analysis and statistics
We analyzed data using GraphPad Prism 6 software (La Jolla, CA) and calculated statistical significance between two data distributions using the unpaired equal-variance two-tail t-test. We used ANOVA for three or more data points. Error bars in all figures represent the standard error of the mean. Standard deviations are presented in Table 1.
References
Frink, E. J. Jr et al. Clinical comparison of sevoflurane and isoflurane in healthy patients. Anesthesia and analgesia 74, 241–245 (1992).
Matta, J. A. et al. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proceedings of the National Academy of Sciences of the United States of America 105, 8784–8789, https://doi.org/10.1073/pnas.0711038105 (2008).
Sonner, J. M. Issues in the design and interpretation of minimum alveolar anesthetic concentration (MAC)studies. Anesthesia & Analgesia. 95, 609–614 (2002).
Gong, D. et al. Rat strain minimally influences anesthetic and convulsant requirements of inhaled compounds in rats. Anesthesia & Analgesia. 87, 963–966 (1998).
Sonner, J. M., Gong, D. & Eger, E. I. Naturally occurring variability in anesthetic potency among inbred mouse strains. Anesthesia and analgesia 91, 720–726 (2000).
Sonner, J. M., Gong, D., Li, J., Eger, E. I. & Laster, M. J. Mouse strain modestly influences minimum alveolar anesthetic concentration and convulsivity of inhaled compounds. Anesthesia and analgesia 89, 1030–1034 (1999).
Kuratani, N., Komatsu, H., Ogli, K., Nogaya, J. & Tanaka, T. Multiple but different genetic factors underlie enflurane and isoflurane requirements studied through backcross analysis in C57BL and ddN mice. Anesthesia and analgesia 83, 798–803 (1996).
Barter, L. S., Ilkiw, J. E., Steffey, E. P., Pypendop, B. H. & Imai, A. Animal dependence of inhaled anaesthetic requirements in cats. British journal of anaesthesia 92, 275–277 (2004).
Katoh, T. & Ikeda, K. The minimum alveolar concentration (MAC) of sevoflurane in humans. Anesthesiology 66, 301–303 (1987).
Scheller, M. S., Saidman, L. J. & Partridge, B. L. MAC of sevoflurane in humans and the New Zealand white rabbit. Canadian journal of anaesthesia = Journal canadien d’anesthesie 35, 153–156, https://doi.org/10.1007/BF03010656 (1988).
Ezri, T. et al. Association of ethnicity with the minimum alveolar concentration of sevoflurane. Anesthesiology 107, 9–14, https://doi.org/10.1097/01.anes.0000267534.31668.62 (2007).
van Swinderen, B. et al. Quantitative trait loci controlling halothane sensitivity in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 94, 8232–8237 (1997).
Cascio, M. et al. Mouse chromosome 7 harbors a quantitative trait locus for isoflurane minimum alveolar concentration. Anesthesia and analgesia 105, 381–385, https://doi.org/10.1213/01.ane.0000261277.65343.4e (2007).
Nash, H. A. In vivo genetics of anaesthetic action. British journal of anaesthesia 89, 143–155 (2002).
Morgan, P. G., Kayser, E. B. & Sedensky, M. M. C. elegans and volatile anesthetics. WormBook: the online review of C. elegans biology, 1–11, https://doi.org/10.1895/wormbook.1.140.1 (2007).
Drexler, B., Antkowiak, B., Engin, E. & Rudolph, U. Identification and characterization of anesthetic targets by mouse molecular genetics approaches. Canadian journal of anaesthesia = Journal canadien d’anesthesie 58, 178–190, https://doi.org/10.1007/s12630-010-9414-1 (2011).
Keaney, N. P. & Ellis, F. R. Malignant hyperpyrexia. Br Med J 4, 49 (1971).
Hogan, K. J. & Vladutiu, G. D. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesthesia and analgesia 109, 1070–1072, https://doi.org/10.1213/ane.0b013e3181ad63b4 (2009).
Wilke, R. A. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6, 904–916, https://doi.org/10.1038/nrd2423 (2007).
Broberg, K. et al. Influence of genetic factors on toluene diisocyanate-related symptoms: evidence from a cross-sectional study. Environ Health 7, 15, https://doi.org/10.1186/1476-069X-7-15 (2008).
Bier, E. D. the golden bug, emerges as a tool for human genetics. Nat Rev Genet 6, 9–23, https://doi.org/10.1038/nrg1503 (2005).
Kayser, E. B., Morgan, P. G. & Sedensky, M. M. GAS-1: a mitochondrial protein controls sensitivity to volatile anesthetics in the nematode Caenorhabditis elegans. Anesthesiology 90, 545–554 (1999).
Falk, M. J., Kayser, E. B., Morgan, P. G. & Sedensky, M. M. Mitochondrial complex I function modulates volatile anesthetic sensitivity in C. elegans. Current biology: CB 16, 1641–1645, https://doi.org/10.1016/j.cub.2006.06.072 (2006).
Quintana, A., Morgan, P. G., Kruse, S. E., Palmiter, R. D. & Sedensky, M. M. Altered anesthetic sensitivity of mice lacking Ndufs4, a subunit of mitochondrial complex I. PloS one 7, e42904, https://doi.org/10.1371/journal.pone.0042904 (2012).
Morgan, P. G., Hoppel, C. L. & Sedensky, M. M. Mitochondrial defects and anesthetic sensitivity. Anesthesiology 96, 1268–1270 (2002).
Weber, K. An apparatus for measurement of resistance to gas-phase reagents. Drosophila Inform Serv 67, 90–92 (1988).
Krishnan, K. S. & Nash, H. A. A genetic study of the anesthetic response: mutants of Drosophila melanogaster altered in sensitivity to halothane. Proceedings of the National Academy of Sciences of the United States of America 87, 8632–8636 (1990).
Dawson, A. G., Heidari, P., Gadagkar, S. R., Murray, M. J. & Call, G. B. An airtight approach to the inebriometer: from construction to application with volatile anesthetics. Fly 7, 112–117, https://doi.org/10.4161/fly.24142 (2013).
Guan, Z., Scott, R. L. & Nash, H. A. A new assay for the genetic study of general anesthesia in Drosophila melanogaster: use in analysis of mutations in the X-chromosomal 12E region. Journal of neurogenetics 14, 25–42 (2000).
Allada, R. & Nash, H. A. Drosophila melanogaster as a model for study of general anesthesia: the quantitative response to clinical anesthetics and alkanes. Anesthesia and analgesia 77, 19–26 (1993).
Leibovitch, B. A., Campbell, D. B., Krishnan, K. S. & Nash, H. A. Mutations that affect ion channels change the sensitivity of Drosophila melanogaster to volatile anesthetics. Journal of neurogenetics 10, 1–13 (1995).
Nash, H. A., Campbell, D. B. & Krishnan, K. S. New mutants of Drosophila that are resistant to the anesthetic effects of halothane. Annals of the New York Academy of Sciences 625, 540–544 (1991).
Friedman, E. B. et al. A conserved behavioral state barrier impedes transitions between anesthetic-induced unconsciousness and wakefulness: evidence for neural inertia. PloS one 5, e11903, https://doi.org/10.1371/journal.pone.0011903 (2010).
Zalucki, O., Day, R., Kottler, B., Karunanithi, S. & van Swinderen, B. Behavioral and electrophysiological analysis of general anesthesia in 3 background strains of Drosophila melanogaster. Fly, 1–9, https://doi.org/10.1080/19336934.2015.1072663 (2015).
Eger, E. I. II Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesthesia and analgesia 93, 947–953 (2001).
Culley, D. J., Loguinov, A., Yukhananov, R. & Crosby, G. General anesthesia does not reduce life expectancy in aged rats. Anesthesia and analgesia 102, 956–959, https://doi.org/10.1213/01.ane.0000195420.63817.3a (2006).
Rampil, I. J., Mason, P. & Singh, H. Anesthetic potency (MAC) is independent of forebrain structures in the rat. Anesthesiology 78, 707–712 (1993).
Antognini, J. F. & Schwartz, K. Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology 79, 1244–1249 (1993).
Zalucki, O. & van Swinderen, B. What is unconsciousness in a fly or a worm? A review of general anesthesia in different animal models. Consciousness and cognition 44, 72–88, https://doi.org/10.1016/j.concog.2016.06.017 (2016).
Kottler, B. et al. A sleep/wake circuit controls isoflurane sensitivity in Drosophila. Current biology: CB 23, 594–598, https://doi.org/10.1016/j.cub.2013.02.021 (2013).
Weber, B. et al. Increased volatile anesthetic requirement in short-sleeping Drosophila mutants. Anesthesiology 110, 313–316, https://doi.org/10.1097/ALN.0b013e3181942df2 (2009).
Robinson, B. J., Uhrich, T. D. & Ebert, T. J. A review of recovery from sevoflurane anaesthesia: comparisons with isoflurane and propofol including meta-analysis. Acta anaesthesiologica Scandinavica 43, 185–190 (1999).
Morgan, P. G. & Sedensky, M. M. Mutations conferring new patterns of sensitivity to volatile anesthetics in Caenorhabditis elegans. Anesthesiology 81, 888–898 (1994).
Katzenberger, R. J. et al. Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction. eLife 4, https://doi.org/10.7554/eLife.04790 (2015).
Mackay, T. F. et al. The Drosophila melanogaster Genetic Reference Panel. Nature 482, 173–178, https://doi.org/10.1038/nature10811 (2012).
Eger, E. I. II, Saidman, L. J. & Brandstater, B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 26, 756–763 (1965).
Gamo, S., Ogaki, M. & Nakashima-Tanaka, E. Strain differences in minimum anesthetic concentrations in Drosophila melanogaster. Anesthesiology 54, 289–293 (1981).
Tinklenberg, J. A., Segal, I. S., Guo, T. Z. & Maze, M. Analysis of anesthetic action on the potassium channels of the Shaker mutant of Drosophila. Annals of the New York Academy of Sciences 625, 532–539 (1991).
Lin, M. & Nash, H. A. Influence of general anesthetics on a specific neural pathway in Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America 93, 10446–10451 (1996).
Campbell, D. B. & Nash, H. A. Use of Drosophila mutants to distinguish among volatile general anesthetics. Proceedings of the National Academy of Sciences of the United States of America 91, 2135–2139 (1994).
Campbell, J. L. & Nash, H. A. The visually-induced jump response of Drosophila melanogaster is sensitive to volatile anesthetics. Journal of neurogenetics 12, 241–251 (1998).
Eger, E. I. II & Johnson, B. H. Rates of awakening from anesthesia with I-653, halothane, isoflurane, and sevoflurane: a test of the effect of anesthetic concentration and duration in rats. Anesthesia and analgesia 66, 977–982 (1987).
Zimin, P. I. et al. Glutamatergic Neurotransmission Links Sensitivity to Volatile Anesthetics with Mitochondrial Function. Current biology: CB 26, 2194–2201, https://doi.org/10.1016/j.cub.2016.06.020 (2016).
Loeffen, J. et al. The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet 63, 1598–1608, https://doi.org/10.1086/302154 (1998).
Falk, M. J. et al. Subcomplex Ilambda specifically controls integrated mitochondrial functions in Caenorhabditis elegans. PloS one 4, e6607, https://doi.org/10.1371/journal.pone.0006607 (2009).
Humphrey, J. A. et al. A putative cation channel and its novel regulator: cross-species conservation of effects on general anesthesia. Current biology: CB 17, 624–629, https://doi.org/10.1016/j.cub.2007.02.037 (2007).
King, E. G., Macdonald, S. J. & Long, A. D. Properties and power of the Drosophila Synthetic Population Resource for the routine dissection of complex traits. Genetics 191, 935–949, https://doi.org/10.1534/genetics.112.138537 (2012).
Pool, J. E. Genetic Mapping by Bulk Segregant Analysis in Drosophila: Experimental Design and Simulation-Based Inference. Genetics 204, 1295–1306, https://doi.org/10.1534/genetics.116.192484 (2016).
Rand, M. D. Drosophotoxicology: the growing potential for Drosophila in neurotoxicology. Neurotoxicol Teratol 32, 74–83, https://doi.org/10.1016/j.ntt.2009.06.004 (2010).
Acknowledgements
We thank Mark Perkins (Department of Anesthesiology) for assistance designing the Serial Anesthesia Array and conducting the gas chromatography experiments. We also thank the Boekhoff-Falk, Ganetzky, and Wassarman labs for comments that greatly improved this study. Funding was provided by the UW-Madison Department of Anesthesiology.
Author information
Authors and Affiliations
Contributions
Z.P.G.O., D.A.W., and M.P. conceived and designed the study. Z.P.G.O. and C.A.L. carried out the experiments and collected the experimental data. All authors contributed to the analysis and interpretation of the data and to the writing of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Olufs, Z.P.G., Loewen, C.A., Ganetzky, B. et al. Genetic variability affects absolute and relative potencies and kinetics of the anesthetics isoflurane and sevoflurane in Drosophila melanogaster. Sci Rep 8, 2348 (2018). https://doi.org/10.1038/s41598-018-20720-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-018-20720-7
This article is cited by
-
Alleviation of arsenic-induced neurobehavioral defects with selenium in the larvae of Zaprionus indianus
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Insights from Drosophila on mitochondrial complex I
Cellular and Molecular Life Sciences (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.